Cadrenal Therapeutics, Inc. (CVKD) income statement
CVKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/30
$1.72−0.16 (-8.51%)
Close on Nov 18, 2026Market cap $6.14MP/E –Yield 959.30%
Cadrenal Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -260.1%
Financial strength
- Current ratio
- 3.73
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 159.5%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.50
- Dividend yield
- 959.30%
See a number that looks wrong?